Molecular Intelligence Tumor Seek Test – Comprehensive Genomic Profiling for Targeted Oncology in Dubai

Executive Summary & Core Metrics

The Molecular Intelligence Tumor Seek Test is a state-of-the-art genomic profiling assay combining next-generation sequencing (NGS) of DNA and RNA from FFPE solid tumor tissue. It provides a comprehensive molecular blueprint, detecting over 500 cancer-related genes, gene fusions, splice variants, and expression levels. This test enables oncologists to identify actionable genetic alterations and tailor personalized therapy. The laboratory operates under strict DHA oversight with ISO 9001:2015 certification, ensuring 99.9% diagnostic sensitivity. Clinical correlation with histopathology and imaging is mandatory.

Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited NGS (DNA & RNA).
Logistics: Archival tissue specimen – Secure Medical Courier Solid Tissue Specimen Retrieval from hospital pathology departments. No home phlebotomy available.
Clinical Guidance: Telephonic post-test consultation for result interpretation.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The MI Tumor Seek test uses a dual-platform approach: next-generation sequencing (DNA and RNA whole transcriptome) combined with liquid chromatography–tandem mass spectrometry (LC‑MS/MS) validation for selected markers. The assay interrogates more than 500 genes, including common oncogenes, tumor suppressor genes, and fusion partners. Results are delivered as a detailed report listing all identified mutations, fusions, and expression changes, along with clinical interpretations and potential therapeutic options. The test requires a formalin-fixed paraffin-embedded (FFPE) tissue block with at least 20% tumor cell content and a minimum surface area of 25 mm². Typical turnaround time is 30 working days from sample receipt at the laboratory.

Feature	Our Test (MI Tumor Seek)	Closest Alternative (Standard NGS Panel)
Precision	DNA + RNA whole transcriptome, 500+ genes, sensitivity 99.9%	DNA-only small panels (50–100 genes), sensitivity ~95%
Methodology	NGS (DNA & RNA-seq), LC‑MS/MS validation	NGS DNA only, no transcriptome
Turnaround	30 Working Days (comprehensive analysis)	14–21 days
Actionable Insights	Detects fusions, expression changes, resistance mutations	Limited to DNA mutations
UAE Compliance	DHA Licensed, ISO 9001:2015, PDPL compliant	Varies

Physician Insight & Safety Protocols

"As a specialist in diagnostic radiology, I recognize that molecular tumor profiling is a powerful adjunct for targeted therapy decisions. However, these results must always be correlated with imaging findings, histopathology, and the full clinical picture. This test provides crucial information, but no single laboratory finding should replace clinical judgment." — Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Advisory & Medication Warning

Do not discontinue prescribed medication without consulting your oncologist. Results from this test should be reviewed by the treating physician before any change in therapy.

This test is intended as a guide for targeted therapy. It is not a diagnostic standalone tool and must be used in conjunction with clinical evaluation. All specimen handling and processing adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability to ensure patient safety and informed consent.

Exclusion Criteria & Emergency Red Flags

Tumor tissue block with less than 20% tumor cells – results may be inconclusive. Contact lab for specimen suitability assessment.
Decalcified or heavily necrotic specimens are not accepted. A fresh biopsy must be obtained.
If patient is on anticoagulant therapy, biopsy site must be carefully managed. Home collection is not applicable – this test requires archival FFPE tissue only.
Emergency warning: If the patient develops acute symptoms (severe pain, bleeding, fever) before or after specimen collection, seek immediate medical attention. Do not wait for test results.

Patient FAQ & Clinical Guidance

1. What does the Molecular Intelligence Tumor Seek Test detect?

This comprehensive panel sequences over 500 cancer-related genes from your FFPE tumor block, identifying DNA mutations, RNA fusions, and expression changes to guide targeted therapy selection. It provides a molecular blueprint of your tumor.

2. How is the sample collected and what are the requirements?

This is an archival tissue specimen test. Your oncologist will arrange for your previously collected FFPE tissue block (from a biopsy or surgery) to be sent to our laboratory via Secure Medical Courier. The block must contain >20% tumor cells and a minimum surface area of 25 mm², accompanied by completed Tumor Profiling Requisition Form (Form 47) and the histopathology report. No new invasive procedure is needed for the test itself.

3. Will my insurance cover the 52,000 AED cost?

Many UAE insurers provide coverage for advanced tumor profiling. We offer direct billing verification – simply WhatsApp us at +971 54 548 8731 with your insurance details for a confidential eligibility check.

4. How long does it take to get results?

The turnaround time is 30 working days from the date the specimen is received and accepted by the laboratory. This ensures comprehensive analysis and validation.

5. What if my tumor block does not meet the requirements?

If the block has insufficient tumor cells or is degraded, the lab will contact your oncologist. A new biopsy may be required. The 30-day turnaround does not begin until an adequate specimen is received.

UAE Regulatory & Data Privacy Adherence

✅ This laboratory operates under DHA/MOHAP licensure, holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139), and strictly adheres to:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring secure handling of patient health data.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the secure transmission of electronic medical records.
Federal Decree-Law No. 4 of 2016 on Medical Liability – governing clinical safety, informed consent, and patient rights.

All test results are released only to the ordering physician. No patient data is shared without explicit consent.

Clinical & Logistical Metadata

Test Name	Molecular Intelligence Tumor Seek Test (MI Tumor Seek)
Price (AED)	52,000 AED
Turnaround Time	30 Working Days
Sample Type / Matrix	FFPE Tumor Tissue Block (Archival Specimen) – Hospital extraction only; mobile phlebotomy disabled for safety. Secure medical courier retrieval.
Methodology Used	Next-Generation Sequencing (NGS) – DNA & RNA whole transcriptome; LC‑MS/MS validation
ICD-10-CM Code	C80.1 (Malignant neoplasm without specification of site)
LOINC Code	98590-2 (Comprehensive genomic profiling panel - Tissue)
DHA Facility License & Address	License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE